Exploring the Efficacy of Methenamine Hippurate Across Different Patient Groups With Recurrent Urinary Tract Infections: Experience From a University Teaching Hospital in South Wales, United Kingdom

The cohort comprised 132 females (88%) with a median age of 60 years. After 12 weeks of treatment, 100 (66.7%) of patients showed improvement, with about half of these (n = 46) experiencing complete resolution of UTIs and a further third (n = 35) reporting reduced frequency or severity at six months follow-up. No statistically significant difference in long-term outcomes was observed based on radiological findings (χ² = 0.138, df = 2, p = 0.933). Similarly, there was no significant association between functional urological status and treatment outcome (χ² = 4.763, df = 2, p = 0.092), nor between catheter use and outcome (χ² = 4.226, df = 2, p = 0.121) Conclusions: MH demonstrates effectiveness for long-term management of rUTIs across diverse patient populations, including those with structural or functional urinary tract abnormalities and catheter users. These findings support the broader application of MH as a viable alternative to antibiotic prophylaxis, potentially reducing antimicrobial resistance while maintaining clinical efficacy.